France $121 Billion Pharmaceutical & Healthcare Giant Sanofi Buys Blueprint Medicines for $9.5 Billion (Includes $400 Million Potential Future Payout via Contigent Value Right), Blueprint Medicines Founded in 2008 by Alexis Borisy & Nick Lydo, IPO on Nasdaq in 2015 at $465 Million Valuation
3rd June | Hong Kong
France pharmaceutical & healthcare giant Sanofi ($121 billion market value) has announced to buy Blueprint Medicines for $9.5 billion (Includes $400 million potential future payout via Contigent Value Right). Blueprint Medicines was founded in 2008 by Alexis Borisy & Nick Lydo. Blueprint Medicines IPO on Nasdaq in 2015 at $465 million valuation. Blueprint Medicines – Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including Ayvakit/Ayvakyt (avapritinib) which we are bringing to patients with SM in the US and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors. Blueprint Medicines is listed on NASDAQ: BPMC. Sanofi – Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
“ France $121 Billion Pharmaceutical & Healthcare Giant Sanofi Buys Blueprint Medicines for $9.5 Billion (Includes $400 Million Potential Future Payout via Contigent Value Right), Blueprint Medicines Founded in 2008 by Alexis Borisy & Nick Lydo, IPO on Nasdaq in 2015 at $465 Million Valuation “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
France $121 Billion Pharmaceutical & Healthcare Giant Sanofi Buys Blueprint Medicines for $9.5 Billion (Includes $400 Million Potential Future Payout via Contigent Value Right), Blueprint Medicines Founded in 2008 by Alexis Borisy & Nick Lydo, IPO on Nasdaq in 2015 at $465 Million Valuation
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
